Literature DB >> 21757952

Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated.

Chadwick E Barnes1, William A Wilmer, Raul A Hernandez, Christopher Valentine, Leena S Hiremath, Tibor Nadasdy, Anjali A Satoskar, Rose L Shim, Brad H Rovin, Lee A Hebert.   

Abstract

BACKGROUND: Relapse or worsening of nephrotic syndrome (NS) in idiopathic membranous nephropathy (IMN) is generally assumed to be due to recurrent disease. Here we document that often that may not be the case. SUBJECTS AND METHODS: This is a prospective study of 7 consecutive IMN patients whose renal status improved, then worsened after completing a course of immunosuppressive therapy. Each underwent detailed testing and repeat kidney biopsy.
RESULTS: In 4 patients (group A), the biopsy showed recurrent IMN (fresh subepithelial deposits). Immunosuppressive therapy was begun. In the other 3 patients (group B), the biopsy showed that the deposits had been eradicated. However, the glomerular basement membrane (GBM) was thickened and vacuolated. Immunosuppressive therapy was withheld. Groups A and B were comparable except that group B had very high intakes of salt and protein, based on 24-hour urine testing. Reducing their high salt intake sharply lowered proteinuria to the subnephrotic range and serum creatinine stabilized.
CONCLUSION: This work is the first to demonstrate that relapse/worsening of NS can occur in IMN even though the GBM deposits have been eradicated. High salt and protein intake in combination with thickened and vacuolated GBM appears to be the mechanism. 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757952      PMCID: PMC3214955          DOI: 10.1159/000324762

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  32 in total

1.  Cyclophosphamide or chlorambucil therapy is indicated in idiopathic membranous nephropathy with strong risk factors for progression.

Authors:  Lee A Hebert; Brad H Rovin; Anil K Agarwal; Dan N Spetie
Journal:  Am J Kidney Dis       Date:  2005-04       Impact factor: 8.860

Review 2.  Management of membranous nephropathy: when and what for treatment.

Authors:  Daniel Cattran
Journal:  J Am Soc Nephrol       Date:  2005-03-30       Impact factor: 10.121

3.  Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy?

Authors:  Daniel C Cattran
Journal:  J Am Soc Nephrol       Date:  2007-05-09       Impact factor: 10.121

4.  Targeting proteinuria as a valid surrogate for individualized kidney protective therapy.

Authors:  Dick de Zeeuw
Journal:  Am J Kidney Dis       Date:  2008-05       Impact factor: 8.860

5.  Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.

Authors:  Liffert Vogt; Femke Waanders; Frans Boomsma; Dick de Zeeuw; Gerjan Navis
Journal:  J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 10.121

6.  Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations.

Authors:  D C Cattran; E Alexopoulos; P Heering; P F Hoyer; A Johnston; A Meyrier; C Ponticelli; T Saito; G Choukroun; P Nachman; M Praga; N Yoshikawa
Journal:  Kidney Int       Date:  2007-09-26       Impact factor: 10.612

7.  Idiopathic membranous nephropathy: diagnosis and treatment.

Authors:  Fernando C Fervenza; Sanjeev Sethi; Ulrich Specks
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

8.  Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares.

Authors:  D J Birmingham; B H Rovin; G Shidham; H N Nagaraja; X Zou; M Bissell; C-Y Yu; L A Hebert
Journal:  Kidney Int       Date:  2007-07-25       Impact factor: 10.612

9.  Supersized kidneys: Lessons from the preclinical obese kidney.

Authors:  V D D'Agati; G S Markowitz
Journal:  Kidney Int       Date:  2008-04       Impact factor: 10.612

Review 10.  Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price?

Authors:  David Philibert; Daniel Cattran
Journal:  Nat Clin Pract Nephrol       Date:  2008-08-26
View more
  3 in total

Review 1.  Differential diagnosis of glomerular disease: a systematic and inclusive approach.

Authors:  Lee A Hebert; Samir Parikh; Jason Prosek; Tibor Nadasdy; Brad H Rovin
Journal:  Am J Nephrol       Date:  2013-09-13       Impact factor: 3.754

2.  A system biology approach to understanding the molecular mechanisms of Gubentongluo decoction acting on IgA Nephropathy.

Authors:  Peicheng Shen; Jiaojiao Shen; Chuan Sun; Xuejun Yang; Liqun He
Journal:  BMC Complement Altern Med       Date:  2016-08-24       Impact factor: 3.659

3.  Is It Coincidence or Consequence for a Case with Antiphospholipid Antibody Syndrome Overlapping SLE to Develop an Immune Complex Nephropathy Followed by a Nonimmune Complex Podocytopathy?

Authors:  Jinil Yoo; Hugo Villanueva; Manimaran Kaliamurthy; John Kang; Lin Lwin
Journal:  Case Rep Nephrol       Date:  2018-07-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.